Furthermore, CRC with high levels of HLA class I expression on the cell membrane may be suitable for vaccine-based and TCR-T cell therapies targeting CLDN1, EphB4, LAT1, FOXM1, HSP105α, ROBO1, and SPARC. Here, SPARC is linked to colorectal carcinoma.